99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer Patients

NCT ID: NCT04591652

Last Updated: 2023-03-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-01
• Study Completion Date: 2024-08-30

Brief Summary

This is an open-labeled Single-Photon Emission Computed Tomography/Computed Tomography(SPECT/CT) study to investigate the clinical value of 99mTc-MIRC208 in HER2 status measurement of cancer patients. A single dose of 14.8 MBq/kg body weight will be injected intravenously. The whole-body SPECT/CT examination will be performed 2 h post-injection and the visual and semiquantitative methods will be used to assess the SPECT/CT images.

Detailed Description

HER2 is an important therapeutic target for cancer. Immunohistochemistry(IHC) and fluorescence in situ hybridization (FISH) are two standard approaches for HER2 status determination and selection of patients who will undergo the anti-HER2 therapy. However, the intra- and intratumor heterogeneity over space and time make them even more challenging to assess HER2 status. HER2-specific nuclear molecular imaging is a potential tool, which has ability to detect HER2 receptor in primary and metastatic lesions noninvasively and address the problems encountered by biopsy dependent tests. VHH, also referred to as nanobody, is a distinct type of antibody fragment derived from camelid heavy chain-only antibody. Compared with classical antibodies, VHHs have smaller size (about 15 kDa), greater thermal and chemical stability, which promoting their application in field of cancer theranostic.

In our recent preclinical studies, Principal Investigator developed a novel VHH-based radiotracer, 99mTc-MIRC208, for the SPECT/CT imaging of HER2 status in tumors. In this clinical study, Principal Investigator aim to investigate whether 99mTc-MIRC208 could be used for HER2 measurement in cancer patients. 99mTc-MIRC208 SPECT/CT examination will be performed in patients with HER2-positive tumors. The SUV of 99mTc-MIRC208 in tumors will be calculated. Meanwhile, Principal Investigator will investigate the ability of 99mTc-MIRC208 for the patients selection for anti-HER2 therapy.

Conditions

Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

99mTc-MIRC208 SPECT/CT scan

The cancer patients will be injected with14.8 MBq/kg body weight, and 2h later, SPECT/CT scan will be performed.

Group Type: EXPERIMENTAL

99mTc-MIRC208

Intervention Type: DRUG

99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.

Interventions

99mTc-MIRC208

99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Aged # 18 years old; ECOG 0 or 1;

2. Patients with HER2 positive or suspicious positive tumors;

3. Has at least one measurable target lesion according to CT or MRI;

4. Life expectancy ≥ 12 weeks.

Exclusion Criteria

1. Significant hepatic or renal dysfunction;

2. Is pregnant or ready to pregnant;

3. Cannot keep their states for half an hour;

4. Refused to join the clinical research;

5. Suffering from claustrophobia or other mental disorders;

6. Any other situation that researchers considered it unsuitable to participate in the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University Cancer Hospital & Institute

OTHER

Sponsor Role: lead

Responsible Party

Hua Zhu

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Hua Zhu

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Shunlian Zhou

Role: primary

zhoushunlian@163.com

010-88196391

Other Identifiers

2020KT81

Identifier Type: -

Identifier Source: org_study_id